Transcription Factor WT1 and Promoter CpG Hypomethylation Coactivate HOXA10 Expression in Ovarian Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|11|1647-1654

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.11, 2014-04, pp. : 1647-1654

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Hypomethylation Agent Bisdemethoxycurcumin Acts on the WIF-1 Promoter, Inhibits the Canonical Wnt Pathway and Induces Apoptosis in Human Non-Small-Cell Lung Cancer

By  

Current Cancer Drug Targets, Vol. 11, Iss. 9, 2011-11 ,pp. : 1098-1110

Bentham Science Publishers

Access to resources Recommend Favorite

The “Methyl-CpG Binding Domain Protein 2” Plays a Repressive Role in Relation to the Promoter CpG Content in the Normal Human Cell Line MRC5

By  

Current Pharmaceutical Design, Vol. 20, Iss. 11, 2014-04 ,pp. : 1598-1603

Bentham Science Publishers

Access to resources Recommend Favorite

Multifunctional transcription factor YY1: a therapeutic target in human cancer?

By Wang Chi-Chung   Chen Jeremy JW   Yang Pan-Chyr  

Expert Opinion on Therapeutic Targets, Vol. 10, Iss. 2, 2006-04 ,pp. : 253-266

Informa Healthcare

Access to resources Recommend Favorite

Targeting SP1 Transcription Factor in Prostate Cancer Therapy

By  

Medicinal Chemistry, Vol. 7, Iss. 5, 2011-09 ,pp. : 518-525

Bentham Science Publishers

Access to resources Recommend Favorite

Hypomethylation of Urokinase (uPA) Promoter in Breast and Prostate Cancer: Prognostic and Therapeutic Implications

By  

Current Cancer Drug Targets, Vol. 5, Iss. 7, 2005-11 ,pp. : 471-488

Bentham Science Publishers

Access to resources Recommend Favorite